#biotech

📰News 📈 Stocks

BioCryst Targets Rare Disease Expansion After Reaching Profitability

September 17, 2026 (54 days ago)

BioCryst aims to diversify its rare disease portfolio using Orladeyo's cash flow, though significant debt obligations and clinical execution risks remain key…

BCRX TAK

🌍 AMERICAS Read More →

🔎Analyst 📈 Stocks

Tempus AI Rallies 30% as Morgan Stanley Upgrades Revenue Outlook

September 17, 2026 (54 days ago)

Tempus AI stock jumped 30% after Morgan Stanley highlighted $330M-$400M in potential annual revenue gains from new diagnostic reimbursement pricing, fueling investor…

TEM

🌍 AMERICAS Read More →

🔐Insider 📈 Stocks

Inhibrx CEO Mark Lappe Purchases $2.6M in Shares Following Trial Success

September 17, 2026 (54 days ago)

CEO Mark Lappe's $2.6 million share purchase underscores internal optimism at Inhibrx Biosciences as the clinical-stage firm advances its proprietary protein engineering…

INBX

🌍 AMERICAS Read More →

📰News 📈 Stocks

Geron Raises 2026 RYTELO Revenue Outlook to $230M-$240M on Strong Adoption

September 16, 2026 (55 days ago)

Geron reports record quarterly revenue of $57.5 million and raises its 2026 RYTELO revenue guidance to $230M-$240M as the company accelerates its…

GERN

🌍 AMERICAS Read More →

🚀IPO 📈 Stocks

Electra Therapeutics Targets $342M IPO to Advance Lead Drug Ipsoprubart

September 15, 2026 (56 days ago)

Electra Therapeutics seeks a $342 million Nasdaq listing to fuel Phase III trials for its lead hyperinflammatory syndrome treatment, ipsoprubart, following strong…

ETRA

🌍 AMERICAS Read More →

📊Earnings 📈 Stocks

MindWalk Reports 21% Revenue Growth and Secures $30M Credit Facility

September 15, 2026 (56 days ago)

MindWalk Holdings posts 21% revenue growth and expands gross margins to 59%, bolstered by a new $30 million credit facility to accelerate…

HYFT

🌍 AMERICAS Read More →

📰News 📈 Stocks

ORIC Pharmaceuticals Launches Phase 3 Prostate Cancer Trial With $387M Runway

September 15, 2026 (56 days ago)

ORIC Pharmaceuticals advances its clinical pipeline with a new Phase 3 prostate cancer trial, balancing a robust cash runway against significant share…

ORIC BAYN

🌍 AMERICAS Read More →

📰News 📈 Stocks

Geron Projects RYTELO Revenue at $240M High End Amid Community Expansion

September 15, 2026 (56 days ago)

Geron Corporation targets the high end of its 2026 revenue guidance as it shifts commercial focus toward community-based treatment settings and earlier…

GERN

🌍 AMERICAS Read More →

📰News 📈 Stocks

Definium Therapeutics Shares Rally 190% YTD on Positive Phase 2 LSD Trial Data

September 14, 2026 (57 days ago)

Definium Therapeutics shares climb as synthetic LSD treatment shows superior efficacy in Phase 2 anxiety trials, marking another milestone for the biotech…

DFTX

🌍 AMERICAS Read More →

📰News 📈 Stocks

Scholar Rock Shares Jump 9% Following FDA Approval of ISEMBYLD

September 14, 2026 (57 days ago)

Scholar Rock rallies 9% as FDA approval of its muscle-targeted therapy for spinal muscular atrophy prompts a wave of analyst price target…

SRRK SPX DJI +1

🌍 AMERICAS Read More →

📰News 📈 Stocks

Olema Shares Slide 15% as AstraZeneca Breast Cancer Trial Fails

September 14, 2026 (57 days ago)

Olema Pharmaceuticals shares fell 15.1% after AstraZeneca's camizestrant failed a key breast cancer trial, prompting Stifel to cut its price target on…

OLMA AZN

🌍 AMERICAS Read More →

🚀IPO 📈 Stocks

Electra Therapeutics Targets $977.6 Million Valuation in Nasdaq IPO

September 14, 2026 (57 days ago)

Electra Therapeutics seeks a $977.6 million valuation as it joins a rebounding biotech IPO market, with plans to list on the Nasdaq…

ETRA

🌍 AMERICAS Read More →